RxDoctor Payments DataLook up a doctor →

Haresh Jhangiani, MD

Hematology-Oncology · Fountain Valley, CANPI 1578566998

Payments from drug & device makers

$746,398in general payments, 2019–2025

Across 2,186 payments — averaging $341.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$183K
  • Takeda Pharmaceuticals U.S.A., Inc.$97K
  • Hexal AG$50K
  • Otsuka Pharmaceutical Co., Ltd.$47K
  • EMD Serono, Inc.$46K
  • Acerta Pharma LLC$39K
  • plus $281K from 54 others
$2,151in research payments, 2019–2025

Across 1 payment — averaging $2151.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited4$183,405
Takeda Pharmaceuticals U.S.A., Inc.67$96,853
Hexal AG39$50,381
Otsuka Pharmaceutical Co., Ltd.7$47,316
EMD Serono, Inc.24$46,243
Acerta Pharma LLC4$39,039
Janssen Research & Development, LLC1$23,981
Helsinn Healthcare SA3$22,500
Array Biopharma Inc36$21,495
Boehringer Ingelheim19$19,676
Genentech, Inc.9$17,627
Clovis Oncology, Inc.7$16,992
Seagen Inc.54$16,602
Bristol Myers Squibb114$14,325
Bayer54$13,305
Pfizer82$13,258
E.r. Squibb & Sons, L.L.C.135$12,154
Novartis132$10,458
GSK72$8,883
Incyte Corporation102$8,681
Puma Biotechnology, Inc.35$8,232
Stemline Therapeutics Inc.20$7,618
Gilead(2 entities)67$6,794
Coherus Oncology, Inc.23$6,011
AstraZeneca(2 entities)135$5,197
Merck Healthcare Kgaa2$3,998
Johnson & Johnson(3 entities)150$3,717
Karyopharm Therapeutics Inc.27$2,874
Merck91$2,043
Amgen59$1,485
Athenex Pharmaceutical Division, LLC1$1,250
Eisai Inc.52$1,177
Pharmacyclics LLC, An Abbvie Company73$1,113
Astellas Pharma US Inc34$922
AbbVie47$806
Sanofi37$801
Daiichi Sankyo Inc.34$735
Exelixis Inc.26$693
Genentech USA, Inc.29$639
Beigene USA, Inc.25$569
Spectrum Pharmaceuticals Inc.4$522
Regeneron Healthcare Solutions, Inc.15$445
Jazz Pharmaceuticals Inc.9$413
Lilly USA, LLC18$335
Blueprint Medicines Corporation11$305
Eli Lilly2$303
AVEO Pharmaceuticals, Inc.13$303
Rigel Pharmaceuticals, Inc.16$290
Taiho Oncology, Inc.12$229
Epizyme, Inc.8$198
Sobi, Inc9$183
Deciphera Pharmaceuticals Inc.8$163
Agios Pharmaceuticals, Inc.7$156
Beone Medicines USA, Inc.5$144
Tersera Therapeutics LLC4$137
Adaptive Biotechnologies Corporation5$131
Octapharma USA, Inc.7$130
Myovant Sciences Inc.8$129
Pharmaessentia USA Corporation4$126
Morphosys, US Inc.5$107

How this compares

$746,398 in reported general payments places this provider in the 85th percentile of 53 hematology-oncology providers in California.

See all hematology-oncology providers in California →

Medicare billing

Part B allowed, 2024
$1,856,595
Medicare patients
177
Services billed
64,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology-oncology in Fountain Valley

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →